Literature DB >> 31927567

Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections.

Russell E Lewis1, Dimitrios P Kontoyiannis2.   

Abstract

Year:  2020        PMID： 31927567      PMCID： PMC7583398          DOI： 10.1093/cid/ciaa031

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).

Authors:  Georgios Chamilos; Mario Luna; Russell E Lewis; Gerald P Bodey; Roy Chemaly; Jeffrey J Tarrand; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Haematologica       Date:  2006-06-01       Impact factor: 9.941

2.  Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.

Authors:  Anne-Sophie Brunel; Agnieszka Wójtowicz; Frédéric Lamoth; Olivier Spertini; Dionysios Neofytos; Thierry Calandra; Oscar Marchetti; Pierre-Yves Bochud
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

3.  A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study).

Authors:  Chiara Cattaneo; Simona Monte; Alessandra Algarotti; Ernesta Audisio; Erika Borlenghi; Leonardo Campiotti; Elisa Cerqui; Caterina Fanizza; Rachele Giuliani; Caterina Micò; Roberta Rocconi; Anna Salvi; Flavia Salvi; Luisa Verga; Alessandro Levis; Giorgio Lambertenghi Deliliers; Enrico M Pogliani; Gianni Tognoni; Alessandro Rambaldi; Giuseppe Rossi
Journal:  J Antimicrob Chemother       Date:  2011-07-05       Impact factor: 5.790

4.  FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.

Authors:  Peter B Bach; Sergio A Giralt; Leonard B Saltz
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

5.  Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis.

Authors:  Ghady Haidar; Kathleen Dorritie; Rafic Farah; Tatiana Bogdanovich; M Hong Nguyen; Palash Samanta
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

6.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

Authors:  Joshua A Hill; Daniel Li; Kevin A Hay; Margaret L Green; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Michael Boeckh; Cameron J Turtle
Journal:  Blood       Date:  2017-10-16       Impact factor: 22.113

7.  Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study.

Authors:  Sarah P Georgiadou; Georgios Pongas; Nancy E Fitzgerald; Russell E Lewis; Michael Rytting; Edith M Marom; Dimitrios P Kontoyiannis
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

8.  Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.

Authors:  Ashrit Multani; Libby S Allard; Tamna Wangjam; R Alejandro Sica; David J Epstein; Andrew R Rezvani; Dora Y Ho
Journal:  Blood Adv       Date:  2019-11-26

9.  Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study.

Authors:  Russell E Lewis; Lizebeth Cahyame-Zuniga; Konstantinos Leventakos; Georgios Chamilos; Ronen Ben-Ami; Pheroze Tamboli; Jeffrey Tarrand; Gerald P Bodey; Mario Luna; Dimitrios P Kontoyiannis
Journal:  Mycoses       Date:  2013-04-04       Impact factor: 4.377

10.  How to prophylax against invasive fungal infections in adult ALL? An unmet need.

Authors:  Oliver A Cornely; Dimitrios P Kontoyiannis
Journal:  Mycoses       Date:  2018-06-13       Impact factor: 4.377
  10 in total
  5 in total

1.  How I transplant a patient with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-08-26       Impact factor: 22.113

2.  How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard E Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

3.  American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.

Authors:  Sanjeet S Dadwal; Tobias M Hohl; Cynthia E Fisher; Michael Boeckh; Genofeva Papanicolaou; Paul A Carpenter; Brian T Fisher; Monica A Slavin; D P Kontoyiannis
Journal:  Transplant Cell Ther       Date:  2021-03

Review 4.  Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions.

Authors:  Will Garner; Palash Samanta; Ghady Haidar
Journal:  J Fungi (Basel)       Date:  2021-02-23

5.  Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies.

Authors:  Feng Zhu; Guoqing Wei; Yandan Liu; Houli Zhou; Wenjun Wu; Luxin Yang; He Huang; Yongxian Hu
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.